Bausch+Lomb Results Presentation Deck
Total Bausch+Lomb P&L¹ (GAAP) - YTD
Bausch + Lomb
Vision Care Revenue
Surgical Revenue
Ophthalmic Pharmaceuticals Revenue
Total Revenue
Gross Profit
Gross Margin
R&D
R&D percent of Revenues
SG&A
SG&A percent of Revenues
Operating Income
Depreciation
Stock Based Compensation
Net Income
Net Income Margin
EPS³
2Q22-1022
$1,149M
$358M
$323M
$1,830M
$974M
53.2%
$152M
8.3%
$711M
38.9%
$110M
$64M
$27M
$25M
1.4%
$0.07
BAUSCH + LOMB 1. Products with sales outside the United States impacted by F/X changes.
2Q21-1Q21
$1,112M
$347M
$356M
$1,815M
$959M
52.8%
$138M
7.6%
$676M
37.2%
$143M
$64M
$29M
$71M
3.9%
$0.20
2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
3. On a proforma basis after giving effect to the IPO.
Reported Change
3%
3%
(9%)
1%
2%
40 bps
(10%)
(5%)
(23%)
0%
(7%)
(65%)
Constant Currency²
8%
8%
(6%)
5%
5%
(13%)
(9%)
(17%)
5%
(7%)
(59%)
Organic Change²
8%
10%
(6%)
5%
30View entire presentation